Sulfonylureas: A new look at old therapy topical collection on pharmacologic treatment of type 2 diabetes

Current Diabetes Reports

Volumn 14, Issue 4, 2014, Pages

  Thulé, Peter M ^a,b   Umpierrez, Guillermo ^b  

^a ATLANTA VA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse events; Diabetes mellitus; Hyperglycemia; Hypoglycemia; Oral Antidiabetic agents; Sulfonylureas

Indexed keywords

GLUCAGON; INSULIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

CANCER RISK; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DIABETES CONTROL; DISEASE ASSOCIATION; DRUG COMBINATION; DRUG EFFECT; DRUG EFFICACY; DRUG INFORMATION; DRUG MECHANISM; GLUCAGON RELEASE; HEALTH IMPACT ASSESSMENT; HUMAN; HYPOGLYCEMIA; INSULIN CLEARANCE; INSULIN SENSITIVITY; MEDICATION THERAPY MANAGEMENT; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; REVIEW; BLOOD; DIABETIC ANGIOPATHY; FEMALE; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; RISK FACTOR; TREATMENT OUTCOME; WEIGHT GAIN;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; RISK FACTORS; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84897108344     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-014-0473-5     Document Type: Review

References (79)

1. Campbell I. Sulfonylureas and hypoglycemia. Diabet Hypoglycemia. 2009;2:3-10.
2. Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2. Drugs. 1981;22:295-320.
3. Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 1. Drugs. 1981;22:211-45.
4. Janbon MCJ, Vedel A, Schaap J. Accidents hypoglycémiques graves par un sulfamidothiodiazol (le VK 57 ou 2254 RP). Montpellier Med. 1942;441:21-2.
5. Loubatieres A, Mariani MM, Chapal J. [Insulin secretion as studied on isolated perfused rat pancreas. I. Synergism between glucose and hypoglycaemic sulphonamides]. Diabetologia. 1970;6:457-66.
6. Gerich JE. Oral hypoglycemic agents. N Engl J Med. 1989;321:1231-45.
7. Seltzer HS. Efficacy and safety of oral hypoglycemic agents. Annu Rev Med. 1980;31:261-72.
8. Tommasini R. Pharmacological activity of glipizide. Curr Med Res Opin. 1975;3 Suppl 1:7-19.
9. Massi-Benedetti M. Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. Clin Ther. 2003;25:799-816.
10. Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations (GIFTS) [corrected]. Vasc Health Risk Manag. 2012;8:463-72.
11. Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin N Am. 2001;30:909-33.
12. Nyenwe EA, Jerkins TW, Umpierrez GE, Kitabchi AE. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism. 2011;60:1-23. Up-to-date review of pharmacological agents available for the management of patients with diabetes type 2.
13. Seino S, Takahashi H, Takahashi T, Shibasaki T. Treating diabetes today: a matter of selectivity of sulphonylureas. Diabetes Obes Metabol. 2012;14 Suppl 1:9-13.
14. Burke MA, Mutharasan RK, Ardehali H. The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the KATP channel. Circ Res. 2008;102:164-76.
15. Seino S, Zhang C, Shibasaki T. Sulfonylurea action re-visited. J Diabetes Invest. 2010;1:37-9.
16. Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest. 2005;115:2047-58.
17. Herbst KJ, Coltharp C, Amzel LM, Zhang J. Direct activation of Epac by sulfonylurea is isoform selective. Chem Biol. 2011;18:243-51.
18. Zhang CL, Katoh M, Shibasaki T, et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science. 2009;325:607-10.
19. Rehmann H. Epac2: a sulfonylurea receptor? Biochem Soc Trans. 2012;40:6-10.
20. Marshall A, Gingerich RL, Wright PH. Hepatic effect of sulfonylureas. Metabolism. 1970;19:1046-52.
21. Simpson HC, Sturley R, Stirling CA, Reckless JP. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients. Diabet Med. 1990;7:143-7.
22. Groop L, Groop PH, Stenman S, et al. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care. 1987;10:671-8.
23. Scheen AJ, Lefebvre PJ, Luyckx AS. Glipizide increases plasma insulin but not C-peptide level after a standardized breakfast in type 2 diabetic patients. Eur J Clin Pharmacol. 1984;26:471-4.
24. Scheen AJ, Castillo MJ, Lefebvre PJ. Decreased or increased insulin metabolism after glipizide in type II diabetes. Diabetes Care. 1988;11:687-9.
25. Barzilai N, Groop PH, Groop L, DeFronzo RA. A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin. Acta Diabetol. 1995;32:273-8.
26. Landstedt-Hallin L, Adamson U, Lins PE. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 1999;84:3140-5.
27. ter Braak EW, Appelman AM, van der Tweel I, Erkelens DW, van Haeften TW. The sulfonylurea glyburide induces impairment of glucagon and growth hormone responses during mild insulin-induced hypoglycemia. Diabetes Care. 2002;25:107-12.
28. Bohannon NV, Lorenzi M, Grodsky GM, Karam JH. Stimulatory effects of tolbutamide infusion on plasma glucagon in insulin-dependent diabetic subjects. J Clin Endocrinol Metab. 1982;54:459-62.
29. Cryer PE. Minireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology. 2012;153:1039-48.
30. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13:610-30.
31. Mandarino LJ, Gerich JE. Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in noninsulin-dependent diabetes mellitus: evidence for improved insulin action at a postreceptor site in hepatic as well as extrahepatic tissues. Diabetes Care. 1984;7 Suppl 1:89-99.
32. Muller G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug amaryl. Mol Med. 2000;6:907-33.
33. Tracewell WG, Stalker DJ, Maloley PA, Gallagher TF, Gwilt PR. Population pharmacokinetics of glyburide in patients with well-controlled diabetes. Pharmacotherapy. 1998;18:51-6.
34. Overkamp D, Volk A, Maerker E, et al. Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabetes Care. 2002;25:2065-73.
35. Pernet A, Trimble ER, Kuntschen F, Assal JP, Hahn C, Renold AE. Sulfonylureas in insulin-dependent (type I) diabetes: evidence for an extrapancreatic effect in vivo. J Clin Endocrinol Metab. 1985;61:247-51.
36. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79.
37. International Diabetes Federation Clinical Guidelines Task Force. Global guidelines for type 2 diabetes. 2005. Available from: http://www.idf.org/Global- guideline. Accessed March 29.
38. Group U. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
39. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-43.
40. Umpierrez GE, Casals MM, Gebhart SP, Mixon PS, Clark WS, Phillips LS. Diabetic ketoacidosis in obese African-Americans. Diabetes. 1995;44:790-5.
41. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care. 2009;32:84-90.
42. Zanchi A, Lehmann R, Philippe J. Antidiabetic drugs and kidney disease-recommendations of the Swiss Society for Endocrinology and Diabetology. Swiss Med Wkly. 2012;142:w13629.
43. Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care. 2003;26:1176-80.
44. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
45. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007;30:389-94.
46. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410-8.
47. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009;151:394-403.
48. Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347:f4533.
49. Nyback-Nakell A, Bergstrom J, Adamson U, Lins PE, Landstedt-Hallin L. Decreasing postprandial C-peptide levels over time are not associated with long-term use of sulphonylurea: an observational study. Diabetes Metab. 2010;36:375-80.
50. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 2005;90:501-6.
51. Shin MS, Yu JH, Jung CH, et al. The duration of sulfonylurea treatment is associated with beta-cell dysfunction in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2012;14:1033-42.
52. Alvarsson M, Sundkvist G, Lager I, et al. Beneficial effects of insulin vs sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care. 2003;26:2231-7.
53. Harrison LB, Adams-Huet B, Raskin P, Lingvay I. Beta-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 2012;35:1406-12. Up-to-date review of pharmacological agents available for the management of patients with diabetes type 2.
54. Nichols CG, Remedi MS. The diabetic beta-cell: hyperstimulated vs hyperexcited. Diabetes Obes Metab. 2012;14 Suppl 3:129-35. Up-to-date review of pharmacological agents available for the management of patients with diabetes type 2.
55. Remedi MS, Nichols CG. Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells. PLoS Med. 2008;5:e206.
56. Remedi MS, Kurata HT, Scott A, et al. Secondary consequences of beta cell inexcitability: identification and prevention in a murine model of K(ATP)-induced neonatal diabetes mellitus. Cell Metabol. 2009;9:140-51.
57. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19(Suppl):789-830.
58. The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of pheniformin therapy. Diabetes. 1975;24 Suppl 1:65-184.
59. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. Can Med Assoc J. 2006;174:169-74.
60. Kassem SA, Raz I. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No. Diabetes Care. 2009;32 Suppl 2:S337-41.
61. Vegh A, Papp JG. Haemodynamic and other effects of sulphonylurea drugs on the heart. Diabetes Res Clin Pract. 1996;31(Suppl):S43-53.
62. Seino S, Takahashi H, Takahashi T, Shibasaki T. Treating diabetes today: a matter of selectivity of sulphonylureas. Diabetes Obes Metab. 2012;14 Suppl 1:9-13.
63. Billman GE. The cardiac sarcolemmal ATP-sensitive potassium channel as a novel target for anti-arrhythmic therapy. Pharmacol Therapeut. 2008;120:54-70.
64. Lomuscio A, Fiorentini C. Influence of oral antidiabetic treatment on electrocardiac alterations induced by myocardial infarction. Diabetes Res Clin Pract. 1996;31(Suppl):S21-6.
65. Aronson D, Mittleman MA, Burger AJ. Effects of sulfonylurea hypoglycemic agents and adenosine triphosphate dependent potassium channel antagonists on ventricular arrhythmias in patients with decompensated heart failure. PACE Pacing Clin Electrophysiol. 2003;26:1254-61.
66. Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab. 2003;88:531-7.
67. Thisted H, Johnsen SP, Rungby J. Sulfonylureas and the risk of myocardial infarction. Metabolism. 2006;55(5 Suppl 1):S16-9.
68. Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364:818-28.
69. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-72.
70. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-39.
71. Nagendran J, Oudit GY, Bakal JA, Light PE, Dyck JR, McAlister FA. Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes? Diabetes Obes Metab. 2013;15:1022-8.
72. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care. 2004;27:201-7.
73. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metabol. 2013;15:938-53.
74. Quast U, Stephan D, Bieger S, Russ U. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes. 2004;53 Suppl 3:S156-64.
75. Singh S, Singh H, Singh PP, Murad MH, Limburg PJ. Anti-diabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prevent. 2013;22(12):2258-68.
76. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97:E1170-5.
77. Bo S, Castiglione A, Ghigo E, et al. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients. Eur J Endocrinol. 2013;169:117-26.
78. Holman RR, Paul SK, Berthel A, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89.
79. TBDS Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-15.